The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Long–Term Beneficial Effect of Interferon Therapy in Patients With Chronic Hepatitis B Virus Infection
Abstract
To examine the long–term effect of interferon (IFN) therapy in patients with chronic hepatitis B virus (HBV) infection, particularly on survival and hepatocellular carcinoma (HCC) prevention, 101 male patients with chronic hepatitis B in a randomized controlled trial were followed up for 1.1 to 11.5 years after the end of therapy. Of the 101 patients, 34 patients received a placebo (control), and 67 patients were treated with IFN (31 patients were treated with IFN alone and 36 patients were treated with IFN after prednisolone priming). Follow–up studies included clinical, biochemical, and virological aspects and HCC screening every 3 to 6 months. Twenty–eight (42%) of the 67 IFN–treated patients and 8 (24%) of the 34 untreated patients seroconverted by the end of the trial. During follow–up, 22 (56%) of the 39 patients who did not seroconvert in the treated group and 5 (19%) of the 26 patients who did not seroconvert in the control group showed a delayed sustained response (P< .005). The cumulative incidence of sustained response was highest in the steroid priming group (P= .049 vs. the IFN-alone group;P= .028 vs. the control group). HCC was detected in 1 (1.5%) of the 67 treated patients and 4 (12%) of the 34 untreated patients (P= .043). The interval between entry and HCC detection was 3.5 to 8.2 years. The cumulative incidence of HCC development was significantly higher in the control group than in the treated group (P= .013). In contrast, the cumulative survival rate was higher in the treated group than the control group (P= .018). Multivariate analysis showed that IFN therapy, preexisting cirrhosis, and the patient's age at entry are significant independent factors for both survival and HCC development. The results suggest that IFN has long–term beneficial effects in terms of HBV clearance, reduction of HCC, and prolonging survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Wong, D. K. H., Cheung, A. M., O'Rourke, K., Naylor, C. D., Detsky, A. S., & Heathcote, J. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-4-199308150-00011 · Cited by 984
Nishiguchi, S., Kuroki, T., Nakatani, S., Morimoto, H., Takeda, T., Nakajima, S., Shiomi, S., Seki, S., Kobayashi, K., & Otani, S. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91739-x · Cited by 857
Long-Term Follow-up of HBeAg-Positive Patients Treated with Interferon Alfa for Chronic Hepatitis B
Niederau, C., Heintges, T., Lange, S., Goldmann, G., Niederau, C. M., Mohr, L., & Häussinger, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605303342202 · Cited by 803
The development of cirrhosis in patients with chronic type B hepatitis: A prospective study
Liaw, Y.-F., Tai, D.-I., Chu, C.-M., & Chen, T.-J. (1988) · Hepatology · doi:10.1002/hep.1840080310 · Cited by 612
Self-citationEpidemiological characteristics and risk factors of hepatocellular carcinoma
CHEN, C., YU, M., & LIAW, Y. (1997) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.1997.tb00513.x · Cited by 470
Self-citationKasahara, A., Hayashi, N., Mochizuki, K., Takayanagi, M., Yoshioka, K., Kakumu, S., Iijima, A., Urushihara, A., Kiyosawa, K., Okuda, M., et al. (1998) · Hepatology · doi:10.1002/hep.510270529 · Cited by 467
Determinants of outcome of compensated hepatitis C virus-related cirrhosis
Serfaty, L., Aumaître, H., Chazouillères, O., Bonnand, A.-M., Rosmorduc, O., Poupon, R. E., & Poupon, R. Y. (1998) · Hepatology · doi:10.1002/hep.510270535 · Cited by 403
Long-Term Remission of Chronic Hepatitis B after Alpha-Interferon Therapy
Korenman, J., Baker, B., Waggoner, J., Everhart, J. E., Di Bisceglie, A. M., & Hoofnagle, J. H. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-8-629 · Cited by 396
Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis
Liaw, Y.-F., Tai, D.-I., Chu, C.-M., Lin, D.-Y., Sheen, I.-S., Chen, T.-J., & Pao, C. C. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90919-4 · Cited by 309
Self-citationIkeda, K., Saitoh, S., Suzuki, Y., Kobayashi, M., Tsubota, A., Fukuda, M., Koida, I., Arase, Y., Chayama, K., Murashima, N., et al. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980301)82:5<827::aid-cncr5>3.0.co;2-g · Cited by 175
Liaw, Y., Pao, C. C., Chu, C., Sheen, I., & Mj, H. (1987) · Hepatology · doi:10.1002/hep.1840070102 · Cited by 84
Self-citationCohard, M., Poynard, T., Mathurin, P., & Zarski, J. (1994) · Hepatology · doi:10.1002/hep.1840200603 · Cited by 59
Oon, C. L. (1992) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00687123 · Cited by 58
Current therapeutic trends in therapy for chronic viral hepatitis
Liaw, Y. (1997) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.1997.tb00520.x · Cited by 54
Self-citation
Cited by
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
Chronic hepatitis B: Update 2009 #
Lok, A. S. F., & McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.23190 · Cited by 2,831
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
Fattovich, G., Stroffolini, T., Zagni, I., & Donato, F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.014 · Cited by 2,591
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266
Self-citation
Metadata
- Authors
- Lin, S.-M., Sheen, I.-S., Chien, R.-N., Chu, C.-M., & Liaw, Y.-F.
- Venue
- Hepatology
- Published
- 1999-03
- Volume
- 29
- Issue
- 3
- Pages
- 971-975
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2082256923
- Cited by
- 444
- References
- 15
- FWCI
- 18.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.